NovartisNVS
Recorded

Novartis 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 14 minParticipants22

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good morning and good afternoon, and welcome to the Novartis Q3 2026 results release conference call and live webcast. Please note that during the presentation, all participants will be in a listen-only mode and the conference is being recorded. After the presentation, there will be an opportunity to ask questions by pressing star 1 and 1 at any time during the conference. Please limit yourself to one question and return to the queue for any follow-ups. A recording of the conference call, including the Q&A session, will be available on our website shortly after the call ends. With that, I would like to hand over to Ms. Isabella Zinck, Investor Relations Executive Director. Please go ahead, madam. Thank you, Sharon.

Isabella ZinckExecutive Director of Investor Relations

Hi, everyone, and welcome to our Q3 earnings call. Let me briefly read the safe harbor statement before we can begin. The information presented today contains forward-looking statements that involve known and unknown risks, uncertainties, and other factors. These may cause actual results to be materially different from any future results, performance, or achievement expressed or implied by such statements. For a description of some of these factors, please refer to the company's Form 20-F and its most recent quarterly results on Form 6-K. That respectively were filed with and furnished to the U.S. Securities and Exchange Commission. And with that, I will hand over to Vas.

Vas NarasimhanCEO

Thank you, Isabella, and thanks everybody for joining today's call. If we could move to slide 4. Hold on one second. We are just getting our slides moving here. In the quarter, Novartis delivered sales growth and core margin expansion. That supported an upgrade to our full-year 2026 bottom-line guidance. You can see sales were up 4% in constant currency. Core operating was up 10%. Mukul will go into the numbers in more detail, but we also had a good margin performance in the quarter. A number of important pipeline milestones, notably of course, as you all know, the remibrutinib data, but also Rhapsido received FDA approval. Pluvicto also with important approvals in the U.S. and China for HSPC. Pelabresib was also filed in Europe. And del-zota received FDA priority review for DMD 44.

Vas NarasimhanCEO

Overall, this allowed us to increase our guidance, and we will go through that in a bit more detail on the call. So moving to the next slide. Priority brands continued to perform well in the quarter. They were up 29%. Very strong performance across Kisqali, Kesimpta, Scemblix, and Leqvio. A solid quarter from Cosentyx. Pluvicto, we are still in the midst of launching in HSPC, so we have not seen that pick up yet, and we will talk more about that in a bit. And Rhapsido also with a very strong performance as well in the quarter. So moving to slide 6. Kisqali grew 37%, and it continued to outperform the CDK4/6 market. You can see that our EBC shares, both in the U.S. and Germany are very stable and at a very healthy level. Now turning to the U.S. first, 38% growth in the quarter, $3 billion year to date.

Vas NarasimhanCEO

We are the leader in EBC, and our NBRx share was up three points versus the prior quarter. 53% of the patients now on Kisqali are from the exclusive population. In metastatic, we are continuing to grow our NBRx share in first line, which is now at 55%. We continue to grow our prescriber base as well. It was up 12% versus the prior year and up 44% in early breast cancer. Outside of the U.S., we had 35% constant currency growth, continued leadership in metastatic breast cancer. Our growth is accelerating now in many of our key markets with the early breast cancer launch now approved in 84 countries and reimbursed in 43 countries. I think some of the benchmarks that demonstrate the performance, Germany 80% EBC share, U.K. 77%. In China, relatively recently after the launch, already reaching 55%.

Vas NarasimhanCEO

We also released last weekend the NATALEE six-year data, which showed a clinically meaningful overall survival with a hazard ratio of 0.809. We expect that data to continue to support our growth in the adjuvant setting. I think notably, having that OS data and showing that CDK4/6 combined with endocrine therapy in those node zero and node one patients gives us a strong case to have physicians provide patients with CDK4/6 inhibitors like Kisqali. Kesimpta grew 22%, fueled by strong demand. U.S. growth was up 21% in the quarter. Our TRX growth is outpacing the market. We were up three points overall in the MS market to 16% share. We were up four and a half points in the B-cell class, getting to 27% share. We see a continued trend to prescribing the medicine earlier in the earlier lines of therapy.

Vas NarasimhanCEO

77% of our NBRx is now our first line or first switch. Outside of the U.S., also very solid performance. We have 80% of EU4 patients are from a first line/first switch, and we see strong growth across Europe as well. We continue to generate evidence to demonstrate Kesimpta's activity in various lines of patients as well in longer-term follow-ups. I think that just allows us to continue to support this medicine and its very strong performance. Moving to slide 8. Pluvicto grew 20% in constant currencies. It was driven more by the ex-U.S. momentum as well as by U.S. pre-taxane growth. The U.S. was up 9% in the quarter. That is primarily driven by the mCRPC pre-taxane setting with use predominantly after the first ARPI.

Vas NarasimhanCEO

The first-line NBRx share is at 15% now, and we expect further share gains over time, and that remains our top priority to continue to drive that early utilization in the mCRPC setting. We are in the very early days of the PSMAddition launch, and I will cover that in a little bit further detail on the next slide. Outside of the U.S., we see great performance, 68% growth. We see accelerating adoption in Europe in many of our key markets, Canada and Japan, as well as early momentum in China. Japan became the fastest market to reach 1,000 patients, supported by ongoing site expansion, and also we are building a facility there. China, we had the approval of the PSMAddition indication in August, and we expect that to support growth as well. Moving to slide 9, turning to the PSMAddition launch.

Vas NarasimhanCEO

I think first it's important to highlight we have strong foundations in place for the brand. Two-thirds of hormone-sensitive prostate cancer patients are managed by physicians who are already using Pluvicto or are connected to established referral pathways. We see broad treatment capacity with 9 out of 10 patients within 30 miles of a site. We are also continuing to address the non-clinical barriers. You can see are the images of both the availability of an infusion and the scaled availability of the pre-filled syringe. It's important to note, we expect about 5-10 weeks of lead time for new patients to be treated, a combination of doing the testing required as well as the scheduling. We do expect the fastest uptake in higher tumor burden patients, as well as the de novo patient segments, where there is unmet need versus the current standard of care.

Vas NarasimhanCEO

We also expect continued expansion in the community, particularly in urology. Overall, I'd say we're encouraged by the early uptake indicators. We do think through quarter 4, we will see some uptake. Also important to note, we will hit the holidays, Thanksgiving and Christmas. We really think next year is when we'll see further acceleration with the HSPC launch. Leqvio continuing to perform extremely well, up 63% in the quarter. This is demand around the world. In the U.S., we're up 60%, outgrowing the advanced lipid-lowering market. Our monthly NBRx growth growing well ahead of the market and our main competitor. I think that's in part driven by Leqvio's persistency and the high compliance rates we're seeing. We see very strong performance in Medicare, which is a good indicator of our performance in buy and bill, where we're up to now 22% share.

Vas NarasimhanCEO

We also see increasing depth in our key healthcare systems. We really focus on patients post-event, where there's a high propensity to want to get patients to their LDL goal. We also had our U.S. label updated with a cardiovascular outcome statement. We're on track for the ORION-4 and V-2P readouts that are expected in quarter 4 and in 2027 respectively. Outside of the U.S., 65% growth. China growth continues post-NRDL. We've noted previously very strong growth in China, as well as the same growth in Europe. We're continuing to expand the Leqvio evidence base. V-CHALLENGE was presented, which showed LDL-C lowering better is superior to bempedoic acid. Moving to slide 11, Scemblix was up 67%, driven by strong U.S. momentum. In the U.S., we continue to see very strong performance in first-line.

Vas NarasimhanCEO

We have reached 33% share. You can see we're edging towards market leadership. We're really at market leadership now. We're maintaining leadership as well in later lines, where we expect continued shift in the treatment mix from second, third line towards first line. Very pleased with the U.S. performance. Outside of the U.S. as well, we're building off of very strong third-line leadership, where we have 77% share across key markets. The early-line indication is now approved in 69 countries outside of the U.S. Japan has sustained first-line NBRx leadership at 56% share, and Germany already at 33% share. Very excited about the trajectory of Scemblix as we move forward. Cosentyx had a solid quarter, up 9% in constant currencies.

Vas NarasimhanCEO

I think when you net out some of the gross to net, we're in the mid-single digit growth range, so I think that's very solid performance with growth in both HS and the SpA indications. The U.S., you can see our HS share is very stable in the high 40s. The SpA business is remaining resilient, so you can see as well in the bottom panel here, our share is steady at 14%. Outside of the U.S., continued growth in Europe and most emerging markets, stable in China. We expect continued indication expansion as we move towards the end of the life cycle for Cosentyx. PMR, polymyalgia rheumatica, was approved by the European Commission. We expect the FDA decision in quarter 4, and the HS IV was added to the label as well in October. Rhapsido has had really strong launch momentum.

Vas NarasimhanCEO

You can see that in quarter 3. We also had the additional approval of symptomatic dermographism, which covers about two-thirds of patients with chronic inducible urticaria. Let's start with CSU. We continue to see the launch trajectory in the U.S. on a steady, strong pace. Over 6,000 subscribers split between allergists and dermatologists. Over 15,000 patients treated. Our NBRx share is about 26%, and that's up about 3 points versus prior quarter. We've been very disciplined with the contracting, so that performance is in the context of about 50% access to label. We do expect further access expansion over quarter 4 and into 2027. Of course, as that access expands, we expect continued acceleration on the sales. Outside of the U.S., we're now launched in 7 markets, and we're steadily getting reimbursement step by step, market by market. We do see strong early uptake in Germany and China.

Vas NarasimhanCEO

When you turn to inducible urticaria, as a reminder, symptomatic dermographism, this is the first-ever approved treatment for this condition. There's about 100,000 U.S. CIndU patients who are uncontrolled on antihistamines out of about 500,000 patients total, and two-thirds of those with SD. We have 100% overlap with the CSU prescribers, so that should enable us to get to a very efficient launch, and we're already rapidly working towards filing the medicine across all 3 subtypes around the globe. So we're upgrading our peak sales guidance for Rhapsido and CSU and CIndU combined to over $4 billion. Moving to the next slide. We had some important readouts in the quarter, which you're well aware of. Remibrutinib, hopefully many of you heard the call on Friday, so you know well, so I won't belabor, but we'll go a little bit in further review on the next slide.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day